[go: up one dir, main page]

PE20071089A1 - Compuesto heterociclico fusionado como inhibidor de tirosina quinasa - Google Patents

Compuesto heterociclico fusionado como inhibidor de tirosina quinasa

Info

Publication number
PE20071089A1
PE20071089A1 PE2006001541A PE2006001541A PE20071089A1 PE 20071089 A1 PE20071089 A1 PE 20071089A1 PE 2006001541 A PE2006001541 A PE 2006001541A PE 2006001541 A PE2006001541 A PE 2006001541A PE 20071089 A1 PE20071089 A1 PE 20071089A1
Authority
PE
Peru
Prior art keywords
alkyl
tyrosine kinase
heterocyclic compound
fused heterocyclic
chlorophenoxy
Prior art date
Application number
PE2006001541A
Other languages
English (en)
Inventor
Tomoyasu Ishikawa
Kazuhiro Miwa
Masaki Seto
Hiroshi Banno
Youichi Kawakita
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20071089A1 publication Critical patent/PE20071089A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A UN COMPUESTO HETEROCICLICO FUSIONADO DE FORMULA (Ia), EN DONDE R1a ES H; R2a ES ALQUILO(C1-C6) SUSTITUIDO CON ALQUILO (C1-C4) OPCIONALMENTE HALOGENADO CON -NR6a-CO-(CH2)n-SO2-; R3a ES H O ALQUILO(C1-C6); R4a ES HALOGENO O ALQUILO(C1-C6); R5a ES HALOGENO O ALQUILO(C1-C6); Xa ES H O HALOGENO CON LA CONDICION DE QUE SE EXCLUYA N-[2-(4-{[3-CLORO-4-(3-CLOROFENOXI)FENIL]AMINO}-5H-PIRROLO[3,2-d]PIRIMIDIN-5-IL)ETIL]-2-(METILSULFONIL)ACETAMIDA. SON SELECCIONADOS: N-[2-(4-{[3-CLORO-4-(3-CLOROFENOXI)FENIL]AMINO}-5H-PIRROLO[3,2-d]PIRIMIDIN-5-IL)ETIL]-2-METIL-2-(METILSULFONIL)PROPANAMIDA, N-[2-(4-{[3-CLORO-4-(3-CLOROFENOXI)FENIL]AMINO}-5H-PIRROLO[3,2-d]PIRIMIDIN-5-IL)ETIL]-2-(ETILSULFONIL)ACETAMIDA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. ESTOS COMPUESTOS SON INHIBIDORES DE LA TIROSINA QUINASA Y SON UTILES EN EL TRATAMIENTO DE CANCER
PE2006001541A 2005-12-02 2006-12-01 Compuesto heterociclico fusionado como inhibidor de tirosina quinasa PE20071089A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005349858 2005-12-02
JP2006060648 2006-03-07

Publications (1)

Publication Number Publication Date
PE20071089A1 true PE20071089A1 (es) 2007-11-19

Family

ID=37897379

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001541A PE20071089A1 (es) 2005-12-02 2006-12-01 Compuesto heterociclico fusionado como inhibidor de tirosina quinasa

Country Status (15)

Country Link
US (1) US20100216788A1 (es)
EP (1) EP1957495A1 (es)
JP (1) JP2009517333A (es)
KR (1) KR20080084823A (es)
AR (1) AR057961A1 (es)
AU (1) AU2006319787A1 (es)
BR (1) BRPI0619911A2 (es)
CA (1) CA2631066A1 (es)
CR (1) CR10057A (es)
MA (1) MA30046B1 (es)
NO (1) NO20082870L (es)
PE (1) PE20071089A1 (es)
RU (1) RU2008126949A (es)
TW (1) TW200730527A (es)
WO (1) WO2007064045A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06013996A (es) * 2004-06-02 2007-02-08 Takeda Pharmaceutical Compuesto heterociclico fusionado.
EP2103620A1 (en) * 2006-12-12 2009-09-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US7825127B2 (en) 2006-12-28 2010-11-02 Takeda Pharmaceutical Company, Limited Method for treating cancer
AU2008264469A1 (en) 2007-06-19 2008-12-24 Takeda Pharmaceutical Company Limited Preventive/remedy for cancer
AR070735A1 (es) * 2008-03-03 2010-04-28 Takeda Pharmaceutical Farmaco combinado para el tratamiento del cancer.
TW200944528A (en) * 2008-03-12 2009-11-01 Takeda Pharmaceutical Fused heterocyclic compound
JP2014520151A (ja) 2011-06-20 2014-08-21 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 蠕虫感染を処置するためのヘテロ環式化合物
US9321750B2 (en) 2012-04-20 2016-04-26 Innov17 Llc ROR modulators and their uses
SG11201600159TA (en) * 2013-07-31 2016-02-26 Merck Patent Gmbh Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof
GB201520499D0 (en) * 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
AR119494A1 (es) * 2019-07-29 2021-12-22 Servier Lab DERIVADOS DE 6,7-DIHIDRO-5H-PIRIDO[2,3-c]PIRIDAZIN-8-ILO, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SUS USOS COMO AGENTES PROAPOPTÓTICOS
WO2022221227A1 (en) 2021-04-13 2022-10-20 Nuvalent, Inc. Amino-substituted heterocycles for treating cancers with egfr mutations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
MXPA06013996A (es) * 2004-06-02 2007-02-08 Takeda Pharmaceutical Compuesto heterociclico fusionado.
WO2006010264A1 (en) * 2004-07-30 2006-02-02 Methylgene, Inc. Inhibitors of vegf receptor and hgf receptor signaling
TW200740820A (en) * 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof

Also Published As

Publication number Publication date
RU2008126949A (ru) 2010-01-10
AR057961A1 (es) 2007-12-26
CA2631066A1 (en) 2007-06-07
US20100216788A1 (en) 2010-08-26
EP1957495A1 (en) 2008-08-20
WO2007064045A1 (en) 2007-06-07
MA30046B1 (fr) 2008-12-01
KR20080084823A (ko) 2008-09-19
NO20082870L (no) 2008-09-01
AU2006319787A1 (en) 2007-06-07
TW200730527A (en) 2007-08-16
BRPI0619911A2 (pt) 2016-08-30
JP2009517333A (ja) 2009-04-30
CR10057A (es) 2008-07-29

Similar Documents

Publication Publication Date Title
UY29246A1 (es) Nuevos compuestos
PE20061367A1 (es) Nuevos derivados del fluoreno y composiciones que los contienen
PE20110222A1 (es) Inhibidores de dipeptidilpeptidasa iv
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
PE20090210A1 (es) Compuestos derivados de pirazolo pirimidina como inhibidores de jak quinasa
MXPA05013733A (es) 2-aminobenzotiazoles como agonistas inversos del receptor de cb1.
PE20141700A1 (es) Compuestos de 2-(2,4,5-anilino sustituido) pirimidina
PE20071089A1 (es) Compuesto heterociclico fusionado como inhibidor de tirosina quinasa
UY30298A1 (es) Inhibidores de la quinasa c-fms ii
PE20090694A1 (es) Compuestos moduladores de sirtuinas
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
PE20151249A1 (es) Derivados de pirazolopirimidina como inhibidores de jak quinasas
PE20091243A1 (es) Compuesto heterociclico fusionado
EA200870376A1 (ru) Бензотиазолы, обладающие активностью по отношению к h3-рецептору гистамина
BRPI0514371A (pt) 2, 4 di (aminofenil) pirimidina como inibidores de plk
SE0202463D0 (sv) Novel compounds
PE20060524A1 (es) Compuestos heterociclico fusionados como intermediarios en la preparacion de pirrolotriazinas inhibidoras de cinasa
EA200500721A1 (ru) Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
ECSP088598A (es) Derivados de piridazinona
NO20044995L (no) Heterosykliske forbindelser
EA200601747A1 (ru) Три(цикло)замещённые амидные соединения
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
PE20110560A1 (es) NUEVOS DERIVADOS DE TRIAZOLO[4,3-a]PIRIDINA, SU PROCEDIMIENTO DE PREPARACION, SU APLICACION COMO MEDICAMENTOS, COMPOSICIONES FARMACEUTICAS Y NUEVA UTILIZACION PARTICULARMENTE COMO INHIBIDORES DE MET
BRPI0407841A (pt) inibidores heterocìclicos de quinase
CL2011003138A1 (es) N-(protegido- n-(3-metoxi-5-metilpirazon-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridino-3-sulfonamida y su proceso de preparacion.

Legal Events

Date Code Title Description
FC Refusal